Organon & Co | OGN - Sales Revenues


Organon & Co reported $1.46B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Celltrion KRW 1.15T 180B Mar/2026
Cspc Pharmaceutical CNY 6.47B 355.1M Mar/2026
Deva Holding AS TRY 2.32B 418.58M Sep/2023
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 28.31B 2.27B Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Kangmei Pharma CNY 1.08B 288.27M Mar/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Laboratorios Farma EUR 448.66M 67.82M Dec/2023
Medical Developments International AUD 21.57M 12.04M Dec/2025
Merck USD 16.29B 110M Mar/2026
Neuren Pharmaceuticals AUD 42.24M 28.1M Dec/2025
Novartis USD 13.11B 750M Mar/2026
Organigram Holdings CAD 63.54M 16.52M Dec/2025
Organon & Co USD 1.46B 50M Mar/2026
Pharma Mar EUR 42.9M 47.3M Mar/2026
Qiagen NV USD 419.22M 38.16M Mar/2026
Sartorius EUR 899.1M 28.5M Mar/2026
Sino Biopharmaceutical CNY 14.26B 3.31B Dec/2025
Tilray USD 217.51M 74.75M Dec/2025
Zealand Pharma A/S 68.91M 19.35M Dec/2025